TipRanks
Advertisement
Advertisement

TVRD Stock Latest News

Tvardi announces publication of preclinical data on STAT3 inhibitor
The FlyTvardi announces publication of preclinical data on STAT3 inhibitor
5d ago
TVRD
Tvardi Therapeutics assumed with a Buy at Lucid Capital
PremiumThe Fly
Tvardi Therapeutics assumed with a Buy at Lucid Capital
22d ago
TVRD
Tvardi Maintained at Buy as Analyst Highlights Differentiated STAT3 Approach in UC; Price Target Reaffirmed at $9
PremiumRatings
Tvardi Maintained at Buy as Analyst Highlights Differentiated STAT3 Approach in UC; Price Target Reaffirmed at $9
1M ago
TVRD
Analyst Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5 on Updated Assumptions and Funding Needs
PremiumRatings
Analyst Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5 on Updated Assumptions and Funding Needs
1M ago
TVRD
Tvardi Therapeutics reports Q2 EPS (69c), consensus (63c)
PremiumThe Fly
Tvardi Therapeutics reports Q2 EPS (69c), consensus (63c)
1M ago
TVRD
Tvardi: Strategic Pivot to Ulcerative Colitis and Upcoming HCC Readouts Support Unchanged $9 Price Target and Buy Rating
PremiumRatingsTvardi: Strategic Pivot to Ulcerative Colitis and Upcoming HCC Readouts Support Unchanged $9 Price Target and Buy Rating
2M ago
TVRD
Tvardi plans 2027 ulcerative colitis trial for oral STAT3 inhibitor TTI-109
Premium
The Fly
Tvardi plans 2027 ulcerative colitis trial for oral STAT3 inhibitor TTI-109
2M ago
TVRD
Tvardi Therapeutics Targets Ulcerative Colitis With STAT3 Inhibitor
Premium
Company Announcements
Tvardi Therapeutics Targets Ulcerative Colitis With STAT3 Inhibitor
2M ago
8K
TVRD
Tvardi Therapeutics Expands At-The-Market Equity Program
PremiumCompany Announcements
Tvardi Therapeutics Expands At-The-Market Equity Program
2M ago
8K
TVRD
Snap, AT&T, Lemonade, Tvardi, Dollar Tree Trending by Analysts
PremiumWeekend Updates
Snap, AT&T, Lemonade, Tvardi, Dollar Tree Trending by Analysts
3M ago
T
DLTR
Tvardi Therapeutics upgraded to Overweight at Piper after Phase 1 data
PremiumThe Fly
Tvardi Therapeutics upgraded to Overweight at Piper after Phase 1 data
3M ago
TVRD
Tvardi Therapeutics upgraded to Overweight from Neutral at Piper Sandler
PremiumThe Fly
Tvardi Therapeutics upgraded to Overweight from Neutral at Piper Sandler
3M ago
TVRD
Why Is Penny Stock Tvardi Therapeutics (TVRD) Up Today?
PremiumMarket NewsWhy Is Penny Stock Tvardi Therapeutics (TVRD) Up Today?
3M ago
TVRD
Tvardi Therapeutics upgraded to Outperform from Market Perform at Raymond James
Premium
The Fly
Tvardi Therapeutics upgraded to Outperform from Market Perform at Raymond James
3M ago
TVRD
Tvardi Therapeutics announces positive Phase 1 results for TTI-109
Premium
The Fly
Tvardi Therapeutics announces positive Phase 1 results for TTI-109
3M ago
TVRD
Tvardi Therapeutics Reports Phase 1 Data for TTI-109
PremiumCompany Announcements
Tvardi Therapeutics Reports Phase 1 Data for TTI-109
3M ago
8K
TVRD
Tvardi, Biogen, FuelCell, Magnite, Canadian Tire Trending
PremiumWeekend Updates
Tvardi, Biogen, FuelCell, Magnite, Canadian Tire Trending
4M ago
BIIB
FCEL
Tvardi Therapeutics Shareholders Approve Directors and Governance Measures
PremiumCompany Announcements
Tvardi Therapeutics Shareholders Approve Directors and Governance Measures
4M ago
8K
TVRD
Tvardi Therapeutics initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Tvardi Therapeutics initiated with a Buy at H.C. Wainwright
4M ago
TVRD
5 Healthcare Stocks Set to Join the Russell 3000
PremiumMarket News5 Healthcare Stocks Set to Join the Russell 3000
4M ago
QSI
AGEN
Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)
Premium
The Fly
Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)
5M ago
TVRD
Tvardi Therapeutics files $200M mixed securities shelf
Premium
The Fly
Tvardi Therapeutics files $200M mixed securities shelf
5M ago
TVRD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >